San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

MIDLAND, Mich.--(BUSINESS WIRE)--Andrew Liveris, chairman and chief executive officer of The Dow Chemical Company (NYSE: DOW), was presented today with the 2017 Global Leadership Award from the U.S.-India Business Council (USIBC). The award was presented to Liveris and Adi Godrej, chairman of the Godrej Group, by John Chambers, USIBC chairman and executive chairman of Cisco, during USIBC’s 42nd Annual Leadership Summit in Washington, D.C. – a prestigious event gathering senior business executives and high-ranking political officials, including Vice President Mike Pence. The award recognizes honorees for creating inclusive business environments, integrating India in the global supply chain and advancing core values such as manufacturing, innovation and scale in tough market conditions. “ On behalf of Dow employees around the world who work every day to strengthen the U.S.-India partnership to create mutually-beneficial, sustainable value, I am honored to accept this award,” said Liveris. “ Advanced manufacturing technologies from Dow and other partners have a pivotal role to play as Prime Minister Modi continues to transform the dynamic Indian economy, including economic diversification, sustainable growth and innovation.” This event aligned with Prime Minister Modi’s first meeting with President Donald Trump in Washington, D.C. to discuss bilateral partnership and common goals of promoting cooperation on trade and economic partnership. Liveris’ recognition reflects his leadership on core U.S.-India political goals, including mutual interest in promoting more value-add domestic manufacturing. Through President Trump's Manufacturing Jobs Initiative, Liveris is working to help identify new ways to spur innovation, revitalize the U.S. manufacturing sector, and drive economic growth and prosperity. To this end, he has led Dow to collaborate with governments on Advanced Manufacturing Plans, including co-chairing the manufacturing committee of the USIBC, which promotes specific areas to progress Prime Minister Modi’s Make it in India initiatives. Past USIBC Global Leadership Award honorees include: Jeff Bezos, founder and CEO of Amazon; Dilip Shanghvi, founder and managing director of Sun Pharmaceuticals; Indra Nooyi, chairman and CEO of PepsiCo; and Shobhana Bhartia, chairperson and editorial director of the Hindustan Times Group. Dow (NYSE: DOW) combines the power of science and technology to passionately innovate what is essential to human progress. The Company is driving innovations that extract value from material, polymer, chemical and biological science to help address many of the world's most challenging problems, such as the need for fresh food, safer and more sustainable transportation, clean water, energy efficiency, more durable infrastructure, and increasing agricultural productivity. Dow's integrated, market-driven portfolio delivers a broad range of technology-based products and solutions to customers in 175 countries and in high-growth sectors such as packaging, infrastructure, transportation, consumer care, electronics, and agriculture. In 2016, Dow had annual sales of $48 billion and employed approximately 56,000 people worldwide. The Company's more than 7,000 product families are manufactured at 189 sites in 34 countries across the globe. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at www.dow.com. ®TM Trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow


"In developed countries, discretionary research funding for cancer is on a rise. Increased investments towards development of better treatment against malignant mesothelioma is observed globally". In 2017, the global malignant mesothelioma market is expected to reach a value of US$ 338 Mn. The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people. By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated US$ 604 Mn in value. Studies focused on cause of malignant mesothelioma are being publicized to boost awareness. Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene is stopping the maturation of mesothelioma tumor. Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies. Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma. In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world. Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men. Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA. The report has profiled leading players in the global malignant mesothelioma market, and they include Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd., Corden Pharma International GmbH, Concordia International Corp., Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd., Nichi-Iko Pharmaceutical Co., Ltd., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, and Pfizer Inc. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10628 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


"In developed countries, discretionary research funding for cancer is on a rise. Increased investments towards development of better treatment against malignant mesothelioma is observed globally". In 2017, the global malignant mesothelioma market is expected to reach a value of US$ 338 Mn. The report observes that increasing use of asbestos for commercial purposes is fuelling the incidence of malignant mesothelioma among people. By the end of 2025, the global market for malignant mesothelioma is anticipated to have soared at 7.5% CAGR, reaching an estimated US$ 604 Mn in value. Studies focused on cause of malignant mesothelioma are being publicized to boost awareness. Through such work, people are becoming more aware, particularly with respect to association of the HOXB4 gene is stopping the maturation of mesothelioma tumor. Overall, the global market for malignant mesothelioma is also witnessing an increased adoption of combination therapies. Many companies are promoting the cumulative use of chemotherapy and immune-oncology procedures in treatment of malignant mesothelioma. In addition to this, malignant mesothelioma is gaining incidence among men. Exposure to asbestos is likely to remain concentrated to male demographics of the world. Increased exposure to such toxic elements is aggravating the incidence of mesothelioma in men. Key players in the global malignant mesothelioma market are also collaborating with leading research organizations to develop combination drugs on mesothelioma, the approval of which is drawing highest regard of authorities such as the FDA. The report has profiled leading players in the global malignant mesothelioma market, and they include Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd., Corden Pharma International GmbH, Concordia International Corp., Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd., Nichi-Iko Pharmaceutical Co., Ltd., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, and Pfizer Inc. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10628 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2013-01-30

The invention provides a continuous reaction system, and more particularly relates to a continuous reaction system comprising subcritical and/or supercritical liquid as solvent and a reactant as solid. The invention can prevent cavitation in the reaction system effectively, and realize maximum conversion of the solid reactant material.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2011-05-18

The invention provides a process for direct liquification of cellulosic biomass, which may be used to liquefy all of the organics in cellulosic biomass, including all high molecular polymeric components such as carbohydrates and lignins, into small molecular organics in a short time under mild conditions. In other words, there is provided a technology capable of converting cellulosic biomass into oil. The resultant renewable high-quality oil may be converted into liquid fuels such as gasoline etc., or used as starting materials in chemical engineering industry. The technology for direct liquification of cellulosic biomass as disclosed in the invention is the first one-step process in the world for direct liquification of cellulosic biomass without black tar formation and gasification.


Trademark
Sun Pharmaceuticals LLC | Date: 2014-01-23

Bicycles.


Trademark
Sun Pharmaceuticals LLC | Date: 2014-01-23

Eyewear.


Trademark
Sun Pharmaceuticals LLC | Date: 2014-03-19

Wireless waterproof speaker cases; Wireless floating speakers; Wireless waterproof speakers; L.E.D. pool dcor; L.E.D. pool inflatables;L.E.D. pool toys. Pool inflatables.


Patent
China Fuel Huaibei Bioenergy Technology Development Co. and Sun Pharmaceuticals Inc. | Date: 2013-01-30

A method of refining cellulosic biomass, comprising synchronous hydrolyzation of at least 85wt% organic polymers , based on the total weight of the cellulosic biomass, in the cellulosic biomass into small molecular organic compounds. The synchronous hydrolyzation is catalytic hydrolyzation for which the catalyst used is a substance represented by L-M-S - H or L-M = S, wherein M represents metal, carbon or silicon, S represents a heteroatom, L represents one or more ligands, and H represents hydrogen.


Patent
Sun Pharmaceuticals Ltd. | Date: 2014-02-04

The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile.

Loading Sun Pharmaceuticals Inc. collaborators
Loading Sun Pharmaceuticals Inc. collaborators